Broadfin Capital’s Albireo Pharma Inc ALBO Stock Holding History

Broadfin Capital’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-66,667	Closed	-$685K	–	87
2015 Q4	$685K	Sell	66,667 -105,184	-61%	-$1.09M	0.04%	88
2015 Q3	$2.27M	Sell	171,851 -14,150	-8%	-$356K	0.13%	80
2015 Q2	$5.75M	Buy	186,001 +141,667	+320%	+$4.76M	0.31%	71
2015 Q1	$1.58M	Hold	44,334	–	–	0.12%	76
2014 Q4	$1.77M	Hold	44,334	–	–	0.15%	73
2014 Q3	$2.22M	Hold	44,334	–	–	0.23%	68
2014 Q2	$2.87M	Hold	44,334	–	–	0.28%	63
2014 Q1	$3.63M	Buy	44,334 +11,001	+33%	+$1M	0.35%	64
2013 Q4	$2.28M	Hold	33,333	–	–	0.3%	53
2013 Q3	$3.15M	Buy	33,333 +18,007	+117%	+$2.34M	0.56%	41
2013 Q2	$1.92M	Buy	+15,326	New	+$1.59M	0.38%	45

Other funds holding ALBO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SKK

Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Broadfin Capital's ALBO Position: Q1 2016 in Review

Broadfin Capital sold out of Albireo Pharma Inc (ALBO) in Q1 2016, closing a stake of 66,667 shares — an estimated $685K sold.

Broadfin Capital first reported a position in ALBO in Q2 2013 and held it in 11 quarters. The position peaked at $5.75M in Q2 2015. 29 funds tracked by Wall St. Rank hold ALBO as of Q1 2016.

Broadfin Capital reported no remaining Albireo Pharma Inc position as of Q1 2016 after selling out during the quarter.
Broadfin Capital sold 66,667 Albireo Pharma Inc shares in Q1 2016, an estimated $685K.
Broadfin Capital first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 11 quarters.
Broadfin Capital's Albireo Pharma Inc position peaked at $5.75M in Q2 2015.
29 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2016.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.